Optimize Farxiga Dose to 10 mg Daily
The patient should have their Farxiga (dapagliflozin) dose increased from 5 mg to 10 mg daily, as this is the recommended dose for cardiovascular and renal protection in patients with type 2 diabetes on established therapy 1.
Rationale for Dose Optimization
The current regimen includes suboptimal dosing of the SGLT2 inhibitor. According to FDA labeling, while 5 mg is an acceptable starting dose for glycemic control, 10 mg once daily is the recommended dose for reducing hospitalization for heart failure in patients with type 2 diabetes and either established cardiovascular disease or multiple cardiovascular risk factors 1. Since this patient is already on basal insulin (indicating more advanced disease), the higher dose provides superior cardio-renal protection beyond glucose lowering.
Additional Considerations Based on Current Regimen
Assess for Overbasalization
With 30 units of bedtime basal insulin, evaluate for signs of overbasalization 2:
- Check bedtime-to-morning glucose differential
- Assess for hypoglycemia (aware or unaware)
- Monitor glucose variability
- Evaluate postprandial-to-preprandial glucose differentials
Consider Adding GLP-1 Receptor Agonist
If A1C remains above goal despite optimized therapy, strongly consider adding a GLP-1 RA with proven cardiovascular benefit (such as semaglutide, liraglutide, or dulaglutide) 2. The 2025 ADA guidelines explicitly recommend GLP-1 RAs in combination with insulin when A1C is not at goal, as they provide:
- Superior A1C reduction (high to very high efficacy)
- Weight loss (intermediate to very high effect)
- Cardiovascular benefit (reduced MACE)
- Renal protection (reduced albuminuria)
- No hypoglycemia risk
A fixed-ratio combination product (insulin degludec/liraglutide or insulin glargine/lixisenatide) could be considered to reduce injection burden 2.
Insulin Titration Algorithm
If fasting glucose remains elevated, titrate basal insulin using evidence-based approach 2:
- Increase by 2 units every 3 days to reach fasting plasma glucose goal
- For hypoglycemia without clear cause: reduce dose by 10-20%
- Reassess every 3-6 months to avoid therapeutic inertia
Safety Monitoring for SGLT2 Inhibitor
When increasing dapagliflozin dose, counsel on 2, 1:
DKA Risk Mitigation:
- Discontinue 3-4 days before major surgery or prolonged fasting
- Stop during critical illness
- Educate on sick-day management
- Be aware of euglycemic DKA presentation
Genital Mycotic Infections:
- Emphasize genital hygiene
- More common at higher doses (11.7-14.6% vs 5.1% placebo) 3
Volume Status:
- Monitor blood pressure and renal function
- Assess for volume depletion, especially if on diuretics
- Adjust other volume-contracting agents as needed
Metformin Dose Consideration
The current metformin dose (500 mg twice daily = 1000 mg/day) is below the typical therapeutic target. Consider increasing to 1500-2000 mg daily if tolerated and eGFR ≥45 mL/min/1.73 m² 2. Use extended-release formulation and administer with food to minimize gastrointestinal side effects.
Critical Pitfall to Avoid
Do not continue 5 mg dapagliflozin long-term when the patient qualifies for 10 mg dosing. The glucose-lowering effect becomes minimal at eGFR <45 mL/min/1.73 m², but cardiovascular and renal benefits persist down to eGFR 25 mL/min/1.73 m² at the 10 mg dose 1. The lower dose provides inadequate organ protection.